Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Refined liver MRI-derived cT1 thresholds capturing hepatic fat fraction enhance mortality risk prediction.

JHEP reports : innovation in hepatology·2026
Same author

Current advances and future directions in the management of HBV-related hepatocellular carcinoma.

Gastroenterology report·2026
Same author

Hierarchical organ aging signatures from routine abdominal CT add incremental disease risk stratification beyond blood biomarkers.

medRxiv : the preprint server for health sciences·2026
Same author

Ventral incisional hernia repair after liver transplant using posterior component separation with transversus abdominis release.

Hernia : the journal of hernias and abdominal wall surgery·2026
Same author

Prognostic Significance of Pretreatment <sup>18</sup>F-FDG PET/CT in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

JHEP reports : innovation in hepatology·2026

Related Experiment Video

Updated: Jun 11, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Hepatocellular carcinoma: A global view.

Ju Dong Yang1, Lewis R Roberts

  • 1Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Nature Reviews. Gastroenterology & Hepatology
|July 15, 2010
PubMed
Summary
This summary is machine-generated.

Hepatocellular carcinoma (HCC) significantly impacts developing nations, primarily due to chronic hepatitis B (HBV) and hepatitis C (HCV) infections. Management strategies must adapt to resource availability, prioritizing prevention and accessible treatments in low-resource settings.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Experiment Videos

Last Updated: Jun 11, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Area of Science:

  • Hepatology and Oncology
  • Global Health
  • Infectious Diseases

Background:

  • Hepatocellular carcinoma (HCC) poses a significant global health challenge, disproportionately affecting developing countries.
  • Over 80% of HCC cases occur in low- and middle-income regions, with chronic HBV and HCV infections as primary drivers.
  • Early viral transmission leads to HCC in productive adult years, creating a substantial economic and healthcare burden.

Purpose of the Study:

  • To outline distinct management strategies for Hepatocellular Carcinoma (HCC) based on resource availability.
  • To emphasize primary prevention and accessible treatment options in resource-limited settings.
  • To advocate for infrastructure development and cost-effective therapies for HCC.

Main Methods:

  • Review of global HCC epidemiology and etiological factors (HBV, HCV).
  • Analysis of healthcare resource disparities and their impact on HCC management.
  • Comparison of high-resource guidelines with needs in low- and middle-income countries.

Main Results:

  • High-resource settings can implement AASLD/EASL guidelines.
  • Low- and middle-income settings require a focus on primary prevention (HBV vaccination, precautions, antivirals).
  • Development of infrastructure for diagnostics (ultrasonography) and treatments (PEI, RFA, resection) is crucial.

Conclusions:

  • Optimal HCC management necessitates tailored strategies considering local resources.
  • Prioritizing primary prevention and accessible, low-cost targeted therapies is vital for resource-limited regions.
  • Establishing essential healthcare infrastructure is key to reducing the HCC burden globally.